Hmm, I think I heard something about that, so I did some looking and you are correct. That is why, at least in the US all LABA's have an added steroid. In my case, the Breyna inhaler (generic Symbicort) includes 80 mcg of budosenide and 4.5 mcg of formoterol. Other dosages are available.

LAMA agents do 2 things, relax the airways, and reducing excess mucus production. There have been few objective studies as yet, but additional research may be verified based on this small observational study:
https://pubmed.ncbi.nlm.nih.gov/33569197
Remember, reducing excess mucus production doesn't necessarily mean totally drying it up. There are many people here who would welcome any reduction in the copious amounts of mucus they produce.
Sue

National Jewish Health supports the selective use combination inhalers in the treatment of Bronchiectasis. ( https://www.nationaljewish.org/conditions/bronchiectasis/bronchiectasis-
overview/treatment )

Many organizations here and in Europe are suggesting that empirical studies of all bronchodilator use in Bronchiectasis be researched further, and that use may not be justified unless a person has underlying asthma or obstructed airways.
https://www.archbronconeumol.org/en-dual-broncodilator-triple-therapy-in-articulo-S0300289623002284 (and others.)